Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (0874.HK)
HKD 18.04
(0.33%)
HKD 18.04
(0.33%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 6.48 Billion CNY | 4.11% |
| 2022 | 5 Billion CNY | 5.72% |
| 2021 | 5.81 Billion CNY | 21.62% |
| 2020 | 4.67 Billion CNY | -6.71% |
| 2019 | 3.9 Billion CNY | 9.73% |
| 2018 | 4.32 Billion CNY | 72.53% |
| 2017 | 2.73 Billion CNY | 25.08% |
| 2016 | 1.39 Billion CNY | 14.83% |
| 2015 | 1.39 Billion CNY | 8.98% |
| 2014 | 1.38 Billion CNY | 20.0% |
| 2013 | 1.11 Billion CNY | 152.84% |
| 2012 | 1.06 Billion CNY | 29.15% |
| 2011 | 444.25 Million CNY | 3.09% |
| 2010 | 431.32 Million CNY | 33.14% |
| 2009 | 339.73 Million CNY | -8.84% |
| 2008 | 309.88 Million CNY | -47.36% |
| 2007 | 577.51 Million CNY | 26.68% |
| 2006 | 540.21 Million CNY | 26.47% |
| 2005 | 427.15 Million CNY | 46.74% |
| 2004 | 291.08 Million CNY | -20.6% |
| 2003 | 366.62 Million CNY | -11.4% |
| 2002 | 413.77 Million CNY | 36.02% |
| 2001 | 303.77 Million CNY | 23.94% |
| 2000 | 247.11 Million CNY | 49.16% |
| 1999 | 164.53 Million CNY | -4.58% |
| 1998 | 172.08 Million CNY | -12.05% |
| 1997 | 195.2 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | 880.76 Million CNY | -0.36% |
| 2024 Q2 | 903.73 Million CNY | -65.45% |
| 2024 Q1 | 2.62 Billion CNY | 442.98% |
| 2023 FY | - CNY | 4.11% |
| 2023 Q2 | 1.33 Billion CNY | -47.32% |
| 2023 Q3 | 1.34 Billion CNY | 1.03% |
| 2023 Q1 | 2.52 Billion CNY | 261.69% |
| 2023 Q4 | 401.78 Million CNY | -70.14% |
| 2022 Q4 | 698.97 Million CNY | -45.2% |
| 2022 Q2 | 1.18 Billion CNY | -50.17% |
| 2022 Q1 | 2.37 Billion CNY | 247.42% |
| 2022 FY | - CNY | 5.72% |
| 2022 Q3 | 1.27 Billion CNY | 7.72% |
| 2021 Q2 | 1.29 Billion CNY | -39.72% |
| 2021 Q1 | 2.14 Billion CNY | 449.47% |
| 2021 Q4 | 683.98 Million CNY | -39.73% |
| 2021 Q3 | 1.13 Billion CNY | -12.37% |
| 2021 FY | - CNY | 21.62% |
| 2020 FY | - CNY | -6.71% |
| 2020 Q3 | 1.28 Billion CNY | 43.35% |
| 2020 Q4 | 390.94 Million CNY | -69.57% |
| 2020 Q1 | 1.65 Billion CNY | 579.17% |
| 2020 Q2 | 896.12 Million CNY | -45.84% |
| 2019 Q2 | 1.59 Billion CNY | -15.86% |
| 2019 FY | - CNY | 9.73% |
| 2019 Q1 | 1.89 Billion CNY | 247.36% |
| 2019 Q3 | 934.31 Million CNY | -41.3% |
| 2019 Q4 | 243.59 Million CNY | -73.93% |
| 2018 Q2 | 2.09 Billion CNY | 113.48% |
| 2018 Q4 | 544.58 Million CNY | -50.62% |
| 2018 FY | - CNY | 72.53% |
| 2018 Q1 | 981.02 Million CNY | -7.52% |
| 2018 Q3 | 1.1 Billion CNY | -47.34% |
| 2017 Q3 | 333.01 Million CNY | -65.37% |
| 2017 FY | - CNY | 25.08% |
| 2017 Q4 | 1.06 Billion CNY | 218.55% |
| 2017 Q2 | 961.75 Million CNY | 118.62% |
| 2017 Q1 | 439.92 Million CNY | -59.86% |
| 2016 FY | - CNY | 14.83% |
| 2016 Q1 | 403.19 Million CNY | -35.64% |
| 2016 Q2 | 671.26 Million CNY | 66.49% |
| 2016 Q3 | 162.24 Million CNY | -75.83% |
| 2016 Q4 | 1.09 Billion CNY | 575.55% |
| 2015 Q2 | 591.55 Million CNY | 47.21% |
| 2015 FY | - CNY | 8.98% |
| 2015 Q1 | 401.85 Million CNY | -40.13% |
| 2015 Q4 | 626.46 Million CNY | 179.84% |
| 2015 Q3 | 223.86 Million CNY | -62.16% |
| 2014 Q1 | 356.56 Million CNY | -36.75% |
| 2014 Q3 | 191.48 Million CNY | -63.57% |
| 2014 Q2 | 525.67 Million CNY | 47.43% |
| 2014 FY | - CNY | 20.0% |
| 2014 Q4 | 671.15 Million CNY | 250.5% |
| 2013 FY | - CNY | 152.84% |
| 2013 Q1 | 156.18 Million CNY | -45.45% |
| 2013 Q2 | 564.57 Million CNY | 261.47% |
| 2013 Q4 | 563.75 Million CNY | 282.64% |
| 2013 Q3 | 147.33 Million CNY | -73.9% |
| 2012 Q3 | 49.2 Million CNY | -73.04% |
| 2012 Q1 | 76.98 Million CNY | -61.31% |
| 2012 FY | - CNY | 29.15% |
| 2012 Q4 | 286.34 Million CNY | 481.89% |
| 2012 Q2 | 182.49 Million CNY | 137.04% |
| 2011 Q2 | 141.6 Million CNY | 109.3% |
| 2011 Q3 | 26.59 Million CNY | -81.22% |
| 2011 Q4 | 198.99 Million CNY | 648.32% |
| 2011 FY | - CNY | 3.09% |
| 2011 Q1 | 67.65 Million CNY | -61.58% |
| 2010 Q1 | 58.73 Million CNY | -70.06% |
| 2010 Q3 | 17.52 Million CNY | -87.81% |
| 2010 FY | - CNY | 33.14% |
| 2010 Q4 | 176.08 Million CNY | 904.68% |
| 2010 Q2 | 143.8 Million CNY | 144.83% |
| 2009 Q1 | 17.23 Million CNY | -92.31% |
| 2009 FY | - CNY | -8.84% |
| 2009 Q4 | 196.17 Million CNY | 1658.72% |
| 2009 Q3 | -12.58 Million CNY | -111.29% |
| 2009 Q2 | 111.44 Million CNY | 546.57% |
| 2008 FY | - CNY | -47.36% |
| 2008 Q4 | 224.16 Million CNY | 484.79% |
| 2008 Q3 | -58.25 Million CNY | -137.35% |
| 2008 Q1 | 102.53 Million CNY | -47.6% |
| 2008 Q2 | 155.99 Million CNY | 52.14% |
| 2007 Q3 | 94.55 Million CNY | -41.54% |
| 2007 FY | - CNY | 26.68% |
| 2007 Q1 | 128.56 Million CNY | -34.19% |
| 2007 Q2 | 161.72 Million CNY | 25.79% |
| 2007 Q4 | 195.69 Million CNY | 106.97% |
| 2006 Q1 | 126.09 Million CNY | 44.09% |
| 2006 Q4 | 195.35 Million CNY | 89.98% |
| 2006 FY | - CNY | 26.47% |
| 2006 Q3 | 102.82 Million CNY | -11.31% |
| 2006 Q2 | 115.94 Million CNY | -8.05% |
| 2005 Q4 | 87.5 Million CNY | -7.52% |
| 2005 Q3 | 94.61 Million CNY | -23.12% |
| 2005 Q2 | 123.06 Million CNY | 0.91% |
| 2005 Q1 | 121.95 Million CNY | 37.6% |
| 2005 FY | - CNY | 46.74% |
| 2004 Q3 | 58.84 Million CNY | -18.29% |
| 2004 Q1 | 87.66 Million CNY | 4.11% |
| 2004 FY | - CNY | -20.6% |
| 2004 Q4 | 88.62 Million CNY | 50.61% |
| 2004 Q2 | 72.02 Million CNY | -17.85% |
| 2003 Q1 | 112.05 Million CNY | 79.48% |
| 2003 Q2 | 91.06 Million CNY | -18.73% |
| 2003 Q3 | 79.29 Million CNY | -12.93% |
| 2003 FY | - CNY | -11.4% |
| 2003 Q4 | 84.2 Million CNY | 6.2% |
| 2002 Q1 | 88.34 Million CNY | 0.0% |
| 2002 Q4 | 62.43 Million CNY | -2.76% |
| 2002 Q3 | 64.2 Million CNY | -34.65% |
| 2002 Q2 | 98.24 Million CNY | 10.06% |
| 2002 FY | - CNY | 36.02% |
| 2001 FY | - CNY | 23.94% |
| 2000 FY | - CNY | 49.16% |
| 1999 FY | - CNY | -4.58% |
| 1998 FY | - CNY | -12.05% |
| 1997 FY | - CNY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 150.4 Million HKD | -4212.585% |
| Grand Pharmaceutical Group Limited | 2.96 Billion HKD | -118.641% |
| Extrawell Pharmaceutical Holdings Limited | -129.51 Million HKD | 5107.819% |
| Wai Yuen Tong Medicine Holdings Limited | 113.79 Million HKD | -5599.685% |
| Qianhai Health Holdings Limited | -50.22 Million HKD | 13013.112% |
| Lee's Pharmaceutical Holdings Limited | 109.82 Million HKD | -5806.144% |
| Essex Bio-Technology Limited | 418.37 Million HKD | -1450.307% |
| Tongfang Kontafarma Holdings Limited | 76.63 Million HKD | -8363.883% |
| PuraPharm Corporation Limited | -26.16 Million HKD | 24885.537% |
| SSY Group Limited | 2.11 Billion HKD | -206.737% |
| JBM (Healthcare) Limited | 204.39 Million HKD | -3073.407% |
| Jacobson Pharma Corporation Limited | 429.92 Million HKD | -1408.679% |
| China Resources Pharmaceutical Group Limited | 15.43 Billion HKD | 57.967% |